TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06968481: Phase 2, Open-label, Randomized, Dose Ascending Trial to Evaluate the Efficacy and Safety of Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage Caused by Uterine Atony in Term Pregnant Women With Uncomplica

Sponsor: Insud Pharma · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 330 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT06968481 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06968481 Rescue Dossier →